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The Firre locus produces a trans-acting RNA
molecule that functions in hematopoiesis
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RNA has been classically known to play central roles in biology, including maintaining telo-
meres, protein synthesis, and in sex chromosome compensation. While thousands of long
noncoding RNAs (lncRNAs) have been identified, attributing RNA-based roles to lncRNA loci
requires assessing whether phenotype(s) could be due to DNA regulatory elements, tran-
scription, or the lncRNA. Here, we use the conserved X chromosome lncRNA locus Firre, as a
model to discriminate between DNA- and RNA-mediated effects in vivo. We demonstrate
that (i) Firre mutant mice have cell-specific hematopoietic phenotypes, and (ii) upon expo-
sure to lipopolysaccharide, mice overexpressing Firre exhibit increased levels of pro-
inflammatory cytokines and impaired survival. (iii) Deletion of Firre does not result in changes
in local gene expression, but rather in changes on autosomes that can be rescued by
expression of transgenic Firre RNA. Together, our results provide genetic evidence that the
Firre locus produces a trans-acting lncRNA that has physiological roles in hematopoiesis.
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Transcription occurs at thousands of sites throughout themammalian genome. Many of these sites are devoid ofprotein-coding genes and instead contain long noncoding
RNAs (lncRNAs). While lncRNA loci have been implicated in a
variety of biological functions, comparatively few lncRNA loci
have been genetically defined to have RNA-based roles. Indeed,
deletions of entire lncRNA loci have uncovered a number of
in vivo phenotypes1–5; however, this approach alone is con-
founded because in addition to the lncRNA transcript, lncRNA
loci can also exert function through DNA regulatory elements6–8,
the promoter region9, as well as by the act of transcription10,11.
Thus, attributing RNA-based role(s) to lncRNA loci requires
testing whether other regulatory modes potentially present at the
locus have molecular activity that could contribute to phenotypic
effects3,12,13.
In this study, we use the functional intergenic repeating RNA
element, (Firre) locus as a model to discriminate between DNA-
and RNA-mediated effects in vivo. We selected this locus for our
study because it is syntenically conserved in a number of mam-
mals, including human14–17, and because studies have reported
diverse biological and molecular roles. Early characterization of
the FIRRE locus in human cell lines identified it as a region that
interacts with the X-linked macrosatellite region, DXZ4, in a
CTCF-dependent manner18–21. Further analyses of the Firre locus
demonstrated that it produces a lncRNA that escapes X-
inactivation15,22–24, although it is predominately expressed from
the active X chromosome21,25. Studies using cell culture models
suggest that the Firre locus has biological roles in multiple pro-
cesses, including adipogenesis26, nuclear architecture15,19,21, and
in the regulation of gene expression programs15,27. In addition,
there is some evidence for roles of the FIRRE locus in human
development and disease28–31. Collectively, these studies
demonstrate the diverse cellular and biological functions for the
Firre locus. However, the biological roles of Firre as well as dis-
entangling DNA- and RNA-mediated function(s) for the Firre
locus have not been explored in vivo.
Using multiple genetic approaches, we describe an in vivo role
for the Firre locus during hematopoiesis. We report that Firre
mutant mice have cell-specific defects in hematopoietic popula-
tions. Deletion of Firre is accompanied by significant changes in
gene expression in a hematopoietic progenitor cell type, which
can be rescued by induction of Firre RNA from an autosomal
transgene within the Firre knockout background. Mice over-
expressing Firre have increased levels of pro-inflammatory cyto-
kines and significantly impaired survival upon exposure to
lipopolysaccharide (LPS). Finally, the Firre locus does not contain
cis-acting RNA or DNA elements (including the promoter) that
regulate neighboring gene expression on the X chromosome (nine
biological contexts examined), suggesting that Firre does not
function in cis. Collectively, our study provides evidence for a
trans-acting RNA-based role for the Firre locus that, thus far, has
physiological importance for hematopoiesis.
Results
The Firre locus produces an abundant lncRNA. We first sought
to investigate the gene expression properties for Firre RNA
in vivo. To determine potential spatial and temporal aspects of
Firre RNA expression during development, we performed in situ
hybridization in wild-type (WT) mouse embryos (E8.0–E12.5).
Notably, we detected Firre RNA in many embryonic tissues,
including the forebrain, midbrain, pre-somitic mesoderm, lung,
forelimb, hindlimb, liver, and heart (Fig. 1a). Since noncoding
RNAs have been described to be generally expressed at lower
levels compared with protein-coding genes32–35, we determined
the relative abundance of Firre RNA in vivo. We performed
RNA-seq on eight different WT embryonic tissues and plotted the
expression of noncoding and coding transcripts. Consistent with
previous reports32–35, we observed that noncoding transcripts
were generally less abundant than protein-coding transcripts
(Fig. 1b). Despite most lncRNAs being expressed at low levels, we
found that Firre, like Malat1 (refs36–38), is an abundant transcript
(Fig. 1b). Next, since Firre is located on the X chromosome and
escapes X-inactivation15,22–24, we investigated whether Firre has
different expression levels in male and female WT tissues. While
levels of Firre RNA varied across embryonic tissue types, within
individual tissues, male and female samples exhibited similar
expression levels of Firre, despite escaping X-inactivation
(Fig. 1c).
Firre knockout and overexpression mice are viable and fertile.
To investigate the in vivo role of Firre and assess DNA- and
RNA-mediated effects, we generated both Firre loss-of-function
and Firre overexpression mice. To delete the Firre locus in vivo,
we generated a mouse line containing a floxed allele (Firrefloxed)
from a previously targeted mouse embryonic stem cell line15 and
mated to a CMV-Cre deleter mouse39. This produced a genomic
deletion (81.8 kb) that removed the entire Firre gene body and
promoter (henceforth called ΔFirre) (Fig. 1d). We confirmed the
deletion of the Firre locus by genotyping (Supplementary Fig. 1)
and examined Firre RNA expression. As expected, we did not
detect Firre RNA in ΔFirre embryos by whole-mount in situ
hybridization or by RNA-seq (Fig. 1a, d).
Since Firre is found on the X chromosome, we first sought to
determine if deletion of the locus had an effect on the expected
sex ratio of the progeny. Matings between ΔFirre mice produced
viable progeny and had a normal frequency of male and female
pups (Supplementary Table 1) that did not exhibit overt
morphological, skeletal, or weight defects (Supplementary Fig. 2).
Moreover, deletion of Firre did not impact expression levels of
Xist RNA in embryonic tissues or perturb Xist RNA localization
during random X chromosome inactivation (XCI) in mouse
embryonic fibroblasts (MEFs) (Supplementary Fig. 3A–C).
Because the ΔFirre allele removes the entire gene body, this
model does not allow us to distinguish between DNA- and RNA-
mediated effects. Therefore, in order to be able to investigate the
role of Firre RNA, we generated a doxycycline (dox)-inducible
Firre overexpression mouse. This mouse model was engineered to
contain a Firre cDNA downstream of a tet-responsive element
(henceforth called tg(Firre)), and was mated to mice that
constitutively express the reverse tetracycline transcriptional
activator (rtTA) gene (combined alleles henceforth called FirreOE)
(Fig. 1e). This approach enabled systemic induction of Firre RNA
in a temporally controllable manner by the administration of dox.
Moreover, by combining the FirreOE and ΔFirre alleles (hence-
forth called Firrerescue), we could test whether Firre RNA
expression alone is sufficient to rescue phenotypes arising in the
ΔFirre mice, thereby distinguishing DNA- and RNA-based effects.
To confirm expression of transgenic Firre RNA, tg(Firre)
females were mated with rtTA males and placed on a dox diet the
day a copulatory plug was detected, and embryos were collected
at E11.5 for analyses. Compared with sibling control embryos, we
detected increased Firre RNA in FirreOE embryos by whole-
mount in situ hybridization (Fig. 1f) and by quantitative reverse
transcription-PCR (qRT-PCR) (heart, 16-fold; forebrain, 26.6-
fold; and forelimb, 11.5-fold) (Fig. 1g). Moreover, matings
between tg(Firre) and rtTA mice fed a dox diet produce viable
progeny that overexpress Firre at expected male and female
frequencies (Supplementary Table 1).
Firre RNA has been reported to be largely enriched in the
nucleus of mouse embryonic stem cells (mESCs)15,40, neuronal
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precursor cells39, and HEK293 cells17, and also has been reported
in the cytoplasm of a human colon cell line27. Thus, we
investigated the subcellular localization of Firre in the genetic
models using RNA fluorescent in situ hybridization (RNA FISH).
In contrast to ΔFirre MEFs, we detected pronounced localization
of Firre RNA in the nucleus of WT MEFs (Fig. 1h). In dox-treated
Firrerescue MEFs, which only produce Firre RNA from the
transgene, we detected Firre RNA in both the nucleus
and cytoplasm (Fig. 1h), which corresponded to approximately
a 2.7-fold increase in Firre RNA relative to WT (Fig. 1i). Notably,
the Firrerescue transgenic model showed both nuclear and
cytoplasmic localization of Firre, suggesting a threshold level
control for nuclear localized Firre.
Tissue-specific gene dysregulation in ΔFirre tissues. Given the
broad expression profile of Firre RNA (Fig. 1a), we took an initial
unbiased approach to explore the potential biological roles for the
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Firre locus, and performed poly(A)+ RNA-seq on eight E11.5
tissues from WT and ΔFirre embryos (forebrain, midbrain, heart,
lung, liver, forelimb, hindlimb, and pre-somitic mesoderm). As
expected, Firre expression was not detected in any of the ΔFirre
tissues (Supplementary Data 1–8). Deletion of Firre was accom-
panied by significant changes in gene expression in all tissues
examined (>1 FPKM, FDR<0.05) (Fig. 2a, b; Supplementary
Data 1–8).
Across these eight tissues, we identified a total of 3910 sig-
nificantly differentially expressed genes, of which 271 genes were
differentially expressed in two or more tissues (Supplementary
Data 1–8). Interestingly, gene ontology (GO) analysis of the
commonly dysregulated genes showed that deletion of the Firre
locus affected genes involved in hemoglobin regulation and
general blood developmental processes (Fig. 2c). We therefore
analyzed publicly available mouse RNA-seq data sets, and found
that Firre is expressed across many blood cell types and note that
expression is found highest in hematopoietic stem cells (HSCs)41
and then decreases in conjunction with hematopoietic differ-
entiation42 (Fig. 2d). Based on this information, we narrowed our
investigation to evaluate potential roles for Firre in the blood
system, and leveraged the genetic mouse models to test DNA-
and RNA-mediated effects.
LPS potentiates the innate immune response in FirreOE mice.
Firre is expressed in many innate immune cell types (Fig. 2d).
Cell-based approaches have shown that Firre can be tran-
scriptionally upregulated upon exposure to lipopolysaccharide
(LPS) and can modulate the levels of inflammatory genes in a
human colorectal adenocarcinoma cell line (SW480)27, mouse
macrophage cell line (RAW264.7)27, as well as in an injury model
using cultured primary rat microglial cells30. Thus, we hypothe-
sized that dysregulation of Firre might alter the inflammatory
response in vivo and reasoned that investigating the inflamma-
tory response in Firre loss- and gain-of-function mice could
provide insight into the DNA- and RNA-mediated effects of
Firre. To test this, we employed a commonly used endotoxic
shock model by administering LPS intraperitoneally to cohorts of
WT, ΔFirre, FirreOE no dox, and dox-fed FirreOE mice in order to
stimulate signaling pathways that regulate inflammatory media-
tors43 (Fig. 2e).
We administered two different LPS preparations, one which
broadly stimulates the pattern recognition receptors toll-like
receptors (TLR) 2, 4, and nitric oxide synthase, and an ultrapure
LPS preparation that specifically stimulates TLR4 (refs44–46). At
5 h post LPS injection, we measured serum cytokine levels.
Notably, we observed that FirreOE dox-fed mice administered
broad-acting LPS had significantly higher levels of inflammatory
cytokines, including TNFα, IL12-p40, and MIP-2 compared with
WT (Fig. 2f). In contrast, we did not observe a significant
difference for these cytokines in LPS-treated ΔFirre mice (Fig. 2f).
Consistent with the increased cytokine response using broad-
acting LPS, dox-fed FirreOE mice administered TLR4-specific-
acting LPS also had significantly higher levels of TNFα, IL12-p40,
and MIP-2 compared with WT (Fig. 2g), albeit at lower serum
concentrations compared with the broad-acting LPS (Fig. 2f, g).
In addition, we confirmed that overexpressing Firre RNA alone
(without LPS) does not result in increased serum levels of TNFα,
IL12-p40, and MIP-2 (Supplementary Fig. 4).
Because increased levels of TNFα is a hallmark of endotoxic
shock47–49, we next tested whether the levels of Firre RNA had an
impact on survival following LPS treatment. We administered
5 mg/kg of TLR4-specific-acting LPS to WT (n= 30), ΔFirre
(n= 18), FirreOE no dox (n= 13), and FirreOE dox-fed (n= 17)
mice, as well as a saline control group and monitored for 6 days.
At this dose, across two independent cohorts, dox-treated FirreOE
mice showed a significantly higher susceptibility to LPS compared
with WT mice (P<0.0001, Mantel–Cox) and uninduced FirreOE
animals (P= 0.0063, Mantel–Cox) (Fig. 2h). Whereas ΔFirre
mice did not show a significant difference in the level of
susceptibility to LPS (P= 0.1967, Mantel–Cox test) (Fig. 2h).
Collectively, these results indicate that endogenous Firre does not
appear to be necessary for a physiological inflammatory response
to LPS, but that ectopic levels of Firre RNA can modulate this
inflammatory response in vivo independent of genomic context,
consistent with an RNA-based role for Firre.
Firre mice have cell-specific hematopoietic phenotypes. Having
observed an effect of Firre in regulating gene expression and
accentuating the inflammatory response, we further investigated
the role of Firre in hematopoiesis (Fig. 3a). We first examined cell
populations in the peripheral blood in ΔFirremice and observed a
modest but significant reduction in the frequencies of CD4 and
CD8 T cells, whereas the frequencies of B and NK cells were
unaffected compared with WT (Fig. 3b; Supplementary Fig. 5A).
To investigate the cause of this reduction, we examined the
thymus (to assess for a defect in T-cell development) and the
bone marrow (to assess for a defect in hematopoietic progenitor
cells). There was no block in thymic development in ΔFirre mice,
as normal frequencies of cells were observed at each develop-
mental stage (Supplementary Fig. 5B, upper panels). However, we
noticed that the absolute number of cells was generally lower in
ΔFirre mice at every developmental stage, suggestive of a
pre-thymic defect in progenitor development (Supplementary
Fig. 5B, lower panels). Consistent with this, in the bone marrow
compartment, we observed a significant reduction in both the
Fig. 1 Mouse models to interrogate the in vivo function of Firre. a Whole-mount in situ hybridization for Firre RNA in WT mouse embryos at E8.0 (n= 4),
E9.5 (n= 4), E10.5 (n= 5), E11.5 (n= 6), E12.5 (n= 4), and ΔFirre E11.5 embryos (n= 3). Scale bar equals 1 mm. b Distribution of transcript abundances for
protein-coding (light gray) and noncoding (dark gray) genes in WT E11.5 heart tissue (representative tissue shown from seven additional tissues). Vertical
lines indicate Firre (red) andMalat1 (blue). c Expression of Firre shown as fragments per kilobase of transcript per million mapped reads (FPKM) from RNA-
seq in E11.5 WT male (n= 3) and female (n= 3) forebrain (FB), midbrain (MB), pre-somitic mesoderm (PSM), lung (LU), forelimb (FL), hindlimb (HL), liver
(LIV), and heart (HRT). The data shown as mean ± standard error of the mean (SEM). d Firre knockout mouse (red). Schematic of mouse X chromosome
ideogram showing the Firre locus relative to Xist. UCSC genome browser diagram of the Firre locus (shown in opposite orientation). Dashed lines indicate
the genomic region that is deleted in ΔFirre mice; single loxP scar upon deletion (gray triangle). Histone modifications and transcription factor binding sites
in mouse embryonic stem cells (mESC-Bruce4, ENCODE/LICR, mm9). RNA-seq tracks for the Firre locus in WT and ΔFirre E11.5 forelimbs. e Schematic of
doxycycline (dox)-inducible Firre overexpression mouse (FirreOE). Tet-responsive element (TRE), minimal CMV promoter (mCMV), reverse tetracycline
transcriptional activator (rtTA), and β-globin polyA terminator (pA). f In situ hybridization for Firre at E11.5 in control (WT or tg(Firre) +dox) (n= 4) and
FirreOE +dox (n= 3) embryos. g qRT-PCR for Firre expression shown as fold change (FC) in dox-treated E11.5 control and FirreOE hrt, fb, and fl. h RNA FISH
for Firre in male WT, ΔFirre, and Firrerescue MEFs. DAPI (blue) marks the nucleus and Firre RNA is shown in green. Scale bar equals 10 µm. i qRT-PCR for
Firre expression shown as FC in male WT, ΔFirre, Firrerescue +dox, and Firrerescue no dox MEFs. Expression normalized to β-actin in the control or WT
sample. The data plotted as mean ± CI at 98%. Source data are provided in the Source Data file
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Fig. 2 Modulation of Firre impacts genes with roles in the blood. a Schematized E11.5 tissues used for RNA-seq. WT (n= 6) shown in black, and ΔFirre
(n= 6) shown in red. The number of differentially expressed genes shown below each tissue. b Heatmap of replicate embryonic tissues. c GO analysis for
genes found dysregulated in four or more tissues. d Firre expression across multiple mouse blood cell lineages (RNA-seq data from bloodspot.eu,
GSE60101). e Experimental approach for cytokine and survival experiments. f Cytokine measurements in serum at 5 h post intraperitoneal (i.p.) injection of
5 mg/kg LPS (broad acting) in WT (n= 8), ΔFirre (n= 8), FirreOE control diet (n= 6), FirreOE dox diet (n= 5–6), and saline-injected WT (n= 2) and ΔFirre
(n= 2) (two independent experiments shown). g Cytokine measurements in serum at 5 h post i.p. injection of 5 mg/kg LPS (specific acting) in WT (n= 6),
FirreOE control diet (n= 5), FirreOE dox diet (n= 4). Cytokine data are plotted as mean ± SEM, and significance determined by an unpaired two-tailed t test.
h 6-day survival plot of mice injected with 5mg/kg LPS (specific acting) in WT (n= 30), ΔFirre (n= 18), FirreOE control diet (n= 13), and FirreOE dox diet
(n= 17) or saline control group (n= 10) consisting of WT, ΔFirre, and FirreOE mice over two independent experiments. Statistical difference determined by
a by a Mantel–Cox test with P < 0.05 deemed significant. Source data are provided in the Source Data file
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frequency and number of the common lymphoid progenitors
(CLPs) (lineage(lin)−Sca1loc-KitloIL7Rα+), a hematopoietic pro-
genitor cell type, in ΔFirre mice (Fig. 3b; Supplementary Fig. 5C).
To assess whether the observed defect in hematopoiesis could
be due to a progenitor-intrinsic effect of Firre deficiency, we
performed a competitive chimera transplant assay using an HSC-
enriched population. We isolated an HSC-enriched population
(lin–Sca1+c-Kit+CD34+/−CD135−) from WT (CD45.2), ΔFirre
(CD45.2), and congenic WT (CD45.1), and then separately mixed
WT (CD45.2) or ΔFirre (CD45.2) cells at an equal ratio with
congenic WT (CD45.1). We then transplanted this cell mixture
into lethally irradiated CD45.1 recipient mice (Supplementary
Fig. 6A, B) and assessed the long-term reconstitution ability of
WT and ΔFirre HSCs to repopulate blood cell lineages in vivo.
We observed that ΔFirre/CD45.2-donors had significant reduc-
tions in the frequencies of CD4 and CD8 T cells, B cells, and
NK cells in the peripheral blood of recipient mice compared
with WT/CD45.2-donors (P= 0.0028, P= 0.0051, P= 0.0114,
P= 0.0068, respectively, two-tailed Mann–Whitney U), indicat-
ing that ΔFirre-donors were markedly outcompeted at repopulat-
ing the blood (Supplementary Fig. 6C). Together, these data
are consistent with a progenitor-intrinsic role for Firre in
hematopoiesis.
In contrast to the ΔFirre model, mice overexpressing Firre
RNA in the WT background (FirreOE) had normal frequencies of
CD4, CD8, and B cells, but had a significant reduction in the
frequency of NK cells in the peripheral blood compared with
control mice (Fig. 3c; Supplementary Fig. 5D). A decrease in the
frequency of NK cells in dox-fed Firrerescue mice, where only Firre
RNA from the transgene is expressed, was also observed
(Supplementary Fig. 7). In the bone marrow of dox-fed FirreOE
mice, we did not observe significant changes in the frequencies of
HSC, multipotent progenitor (MPP), common myeloid progeni-
tor (CMP), or CLPs compared with control samples (Fig. 3c;
Supplementary Fig. 5E). Taken together, these results identify cell
type-specific defects during hematopoiesis, whereby alterations of
Firre impact the ratios and numbers of particular blood cells
produced during hematopoiesis.
Firre RNA has a trans-acting role in vivo. Next, we wanted to
further investigate the DNA- and RNA-mediated effects of the
Firre locus using a cell type that was dysregulated in the ΔFirre
immunophenotyping analysis. We selected to use the CLP as a
model, because this was the earliest hematopoietic defect identi-
fied and because Firre is highly expressed in this progenitor cell
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Fig. 3 ΔFirre and FirreOE mice have cell-specific hematopoietic phenotypes. a Schematic of hematopoiesis. b Frequencies of common myeloid progenitors
(CMP) and common lymphoid progenitors (CLP) in the bone marrow shown from WT (n= 13, black circles) and ΔFirre (n= 12-13, red squares) mice. Two
representative experiments combined (three independent experiments). Frequencies of CD4 and CD8 cells from the peripheral blood from WT (n= 14)
and ΔFirre (n= 15) mice. Frequency of NK cells from the peripheral blood from WT (n= 17) and ΔFirre (n= 18) mice. Three representative experiments
combined (seven independent experiments). c Frequencies of CMPs and CLPs from the bone marrow from control (tg(Firre) or WT or rtTA with dox)
(n= 10, black circle) and FirreOE +dox (n= 6, blue square) mice. One representative experiment is shown (two independent experiments). Frequencies of
CD4, CD8, and NK cells from the peripheral blood from control (WT or tg(Firre) or rtTA with dox) (n= 6, black circle) and FirreOE +dox (n= 5, blue
square) mice. One representative experiment is shown (three independent experiments). Cell frequencies determined by flow cytometry analysis. The data
are plotted as percent (%) of live cells showing the mean ± SEM, and statistical significance determined by a two-tailed Mann–Whitney U test. Source data
are provided in the Source Data file
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type. Therefore, further investigation could provide insight into
the physiological effects of modulating Firre in a progenitor cell
population. Because the ΔFirre mouse contains a deletion that
removes all potential DNA regulatory elements, the lncRNA, and
the promoter (thus removing the act of transcription), this mouse
model does not allow us to distinguish between DNA- and RNA-
mediated effects.
To directly test whether the decrease in the frequencies of CLPs
observed in the ΔFirre mice is mediated by an RNA-based
mechanism, we reasoned that overexpressing Firre RNA in the
ΔFirre background would enable to test for an RNA-mediated
role. To this end, we generated multiple cohorts of mice
that contained the FirreOE alleles in the ΔFirre background
(Firrerescue) and induced transgenic Firre RNA expression by
placing mice on a dox-diet. From multiple cohorts of WT, ΔFirre,
and dox-fed Firrerescue mice, we assessed CLP frequency by flow
cytometry in total bone marrow and lineage-depleted bone
marrow (to enrich for hematopoietic non-lineage committed
cells).
Consistent with the previous data (Fig. 3b), we also observed a
significant decrease in the frequency of CLPs in total bone marrow
from ΔFirre mice (n= 17, mean CLP frequency= 0.0532)
compared with WT mice (n= 16, mean CLP frequency= 0.0829)
(Fig. 4b) and in lineage-depleted bone marrow from ΔFirre mice
(n= 9, mean CLP frequency= 0.3011) compared with WT (n= 9,
mean CLP frequency= 0.2167) (Supplementary Fig. 8A, B). In
contrast, dox-fed Firrerescue mice which only expressed transgenic
Firre RNA, we observed that the frequency of CLPs was
significantly increased (n= 15, mean CLP frequency= 0.0810)
compared with ΔFirre mice, and restored to approximately that of
WT in total bone marrow (Fig. 4b). Consistent with this data, in
lineage-depleted bone marrow, we also observed a significant
increase in the frequency of CLPs in dox-fed Firrerescue mice
(n= 11, mean CLP frequency= 0.2809) compared with ΔFirre
mice (Supplementary Fig. 8). Thus, induction of transgenic
Firre RNA alone is sufficient to rescue the reduction in frequency
of CLPs observed in ΔFirre bone marrow. These data suggest that
Firre RNA, rather than DNA, exerts a biological function during
hematopoiesis.
Transgenic Firre RNA restores gene-expression programs
in vivo. To gain further insight into the molecular roles of Firre in
the CLPs, we took a gene expression approach, because altera-
tions of the Firre locus and RNA have previously been shown to
impact gene expression15,21,50. Moreover, we reasoned that we
could test if changes in gene expression in the loss-of-function
model could be rescued by expressing only transgenic Firre RNA.
To this end, we isolated CLPs by fluorescence-activated cell
sorting (FACS) from the bone marrow of age- and sex-matched
WT, ΔFirre, and dox-fed Firrerescue mice, and performed poly(A)
+ RNA-seq. As expected, Firre RNA was not detected in the
ΔFirre samples, and expression of transgenic Firre RNA in the
Firrerescue samples was detected at levels above WT (Fig. 4c).
Differential gene expression analysis between WT and ΔFirre
CLPs identified 89 significantly differentially expressed genes
(FDR<0.1) (Fig. 4d; Supplementary Data 9). GO analysis of the
differentially expressed genes showed that deletion of Firre in
CLPs affected genes involved in lymphocyte activation, cell
adhesion, and B-cell activation (Fig. 4e).
Next, we determined if induction of Firre RNA in the
Firrerescue model could rescue expression of the 89 significantly
dysregulated genes found in ΔFirre CLPs. We compared the CLP
RNA-seq from ΔFirre and Firrerescue mice and identified 4656
genes with significant changes in gene expression (FDR<0.1)
(Supplementary Data 10). Notably, 78 of the 89 genes that were
significantly differentially expressed in ΔFirre CLPs were found to
be significantly and reciprocally regulated in Firrerescue CLPs
(P= 2.2e-16, Fisher exact test) (Fig. 4d). For example, Ccnd3,
Lyl1, and Ctbp1 are significantly downregulated in ΔFirre CLPs,
but are found significantly upregulated in Firrerescue CLPs to
(Fig. 4f). Further, genes such as Maoa, Fam46c, and Icos were
found significantly upregulated in ΔFirre CLPs, but their
expression was significantly reduced in Firrerescue CLPs (Fig. 4f).
We also noted that several immunoglobin heavy and light-chain
variable region genes were reciprocally regulated in our analyses
(Fig. 4d). Taken together, these data suggest that ectopic
expression of Firre is sufficient to restore a gene expression
program in an RNA-based manner in vivo.
The Firre locus does not function in cis. Many lncRNA loci
exert function to control the expression of neighboring genes, a
biological function called cis-regulation51. This occurs through a
variety of mechanisms including, cis-acting DNA-regulatory ele-
ments, the promoter region, the act of transcription, and the
lncRNA9,10,52–54. The ΔFirre mouse model enables to test for
potential cis-regulatory roles for Firre on the X chromosome,
because the knockout removes the entire Firre locus and pro-
moter region (Fig. 1d). To investigate local (cis) effects on local
gene expression, we generated a 2Mb windows centered on the
Firre locus and examined whether the neighboring genes were
significantly dysregulated across nine biological contexts.
Differential gene expression analysis for WT and ΔFirre CLPs
showed that of the 12 genes within a 2Mb window (excluding
Firre), none were differentially expressed (Fig. 4g). Consistent
with this finding, we did not observe significant changes in local
gene expression (2Mb windows centered on the Firre locus) in
seven of the eight embryonic tissues (Fig. 4g; Supplementary
Fig. 9A–F). Indeed, we observed one instance of differential
expression in one embryonic tissue (Hs6st2 was slightly but
significantly downregulated in the embryonic forebrain, −0.38
log2 fold change, FDR<0.05) (Supplementary Fig. 9A–F). These
data demonstrate that the Firre locus does not exert a local effect
on gene expression in vivo, and suggest that the Firre lncRNA
regulates gene expression in a trans-based manner. Collectively,
our study investigates the roles of DNA and RNA at the Firre
locus in vivo and genetically defines that the Firre locus produces
as a trans-acting lncRNA molecule in vivo.
Discussion
Classic models used to study noncoding RNAs—ribosomal
RNAs, small nucleolar RNAs, tRNAs, and the telomerase RNA
component (TERC)—have demonstrated that RNAs serve
important cellular functions. This core of possible RNA biology
has been greatly expanded by studies that have identified tens of
thousands of lncRNAs32,33,55. Indeed, subsequent molecular and
genetic interrogation of lncRNA loci have identified diverse
molecular roles and biological phenotypes. However, lncRNA loci
can potentially function through multiple molecular modes:
DNA-regulatory elements (including the promoter), the act of
transcription itself, and the lncRNA gene product. Therefore,
attributing an RNA-based role to a lncRNA locus requires the
development of multiple genetic models to determine the activ-
ities and contributions of potential regulatory modalities12,13,52.
In this study, we developed three genetic models in mice for the
syntenically conserved lncRNA Firre: loss-of-function, over-
expression, and rescue. Notably, we report that deletion of the
Firre locus does not impact survival in mice, or despite escaping
XCI, skew the sex ratio of progeny. We leveraged the genetic
models to discriminate between DNA- and RNA-mediated effects
in vivo. We determined that modulating Firre directs cell-specific
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defects during hematopoiesis, potentiates the innate immune
response upon exposure to LPS, and can restore gene expression
programs—all of which have an RNA-based functional modality.
We also conclude that the Firre locus does not have a local cis-
regulatory effect on gene expression in nine different biological
contexts. Together, by using multiple genetic and molecular
approaches, we identified that Firre produces a trans-acting
lncRNA in a hematopoietic context. There are several important
implications for these results.
First, our study indicates that Firre has trans RNA-based
activity in vivo, and thus extends reports that have suggested
RNA-based roles for Firre in cell culture models25,27,40. By using
compound genetic approaches, we found that overexpression of
Firre from a transgene in the Firre-deficient background was
sufficient to rescue physiological and molecular phenotypes in
ΔFirre CLPs in vivo. The rescue of genes found differentially
expressed in ΔFirre CLPs by a Firre transgene produced a highly
significant result (P= 2.2e-16, Fisher exact test); however, we
note that the widespread changes in gene expression observed in
the CLPs from animals only expressing transgenic Firre RNA
could also formally contribute to this effect. Yet, we speculate that
early hematopoietic progenitor cells may represent a unique
context to study the role(s) of FIRRE/Firre. In humans, FIRRE is
expressed as both circular (circ-FIRRE) and linear forms in
hematopoietic cells, and circ-FIRRE is abundant in all progenitor
cell types, except for the CLPs56. More studies will be needed to
determine how and if Firre RNA is interacting at distal loci as well
as assess the functional differences between linear and circular
isoforms of Firre in a progenitor cell context.
Second, we observed that overexpression of Firre RNA in an
endotoxic shock model potentiated the innate immune response
in vivo, and in turn, led to significant viability defects. Consistent
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with our findings, independent studies have found that over-
expression of Firre RNA in different cellular contexts can mod-
ulate genes in the innate immune response. For example, the
levels of select inflammatory genes, including IL12p40, are
increased upon overexpression of Firre RNA followed by LPS
stimulation in human SW480 cells27. In addition, upon over-
expression of Firre RNA in an injury model using cultured pri-
mary microglial cells, TNF-α levels are increased30. The different,
yet synergistic approaches (cell-based, ex vivo, and in vivo)
provide supporting evidence for an RNA-based role for Firre. In
the overexpression approach in this study, we note that the
phenotypes could be due to increased levels of Firre in a cell type
where it is normally expressed and/or from de novo expression in
a cellular context where Firre is not endogenously found. Yet, this
strategy may perhaps mimic disease contexts where FIRRE is
found overexpressed. We speculate that Firre could be important
in setting functional thresholds for cells. For example, FIRRE is
not only significantly increased in certain cancers, including,
kidney renal cell carcinoma, lung squamous cell carcinoma, and
colon adenocarcinoma31, but high levels of FIRRE expression
have been significantly associated with more aggressive disease
and poor survival in patients with large B-cell lymphoma29.
Finally, our study suggests that Firre does not have a cis-reg-
ulatory role on gene expression in vivo. Upon deletion of the Firre
locus and its promoter region, we observed global changes in gene
expression. Yet, we did not find changes in local gene expression
(2Mb window) at the Firre locus in most embryonic tissues and
in CLPs. Thus, potential DNA regulatory elements, the lncRNA,
the promoter, and the act of transcription appear to not have
regulatory roles on neighboring gene expression in the nine
biological contexts (eight embryonic and one cell type) analyzed
in this study. Moreover, we observed that deletion of Firre in vivo
does not perturb Xist RNA expression in eight embryonic tissues
and does not affect random XCI in MEFs, which is consistent
with a previous study using cell culture models21. Together, these
data are notable because cis-acting mechanisms are speculated to
be common feature at lncRNA loci57. While we did not find any
evidence for cis-activity at the Firre locus in vivo, a previous study
from our group found active DNA elements within the Firre locus
using a cell-based enhancer reporter assay in 3T3 cells14. We
speculate that these candidate DNA-regulatory elements are likely
to regulate the Firre locus rather than neighboring genes, as we
did not find evidence that neighboring genes were significantly
dysregulated upon deletion of the Firre locus.
In summary, we have developed genetic models to test the
DNA- and RNA-mediated effects of the syntenically conserved
lncRNA locus, Firre, in vivo. Our findings provide evidence that
the Firre lncRNA locus has a role in hematopoiesis that is
mediated by a trans-acting RNA, and further highlights the
biological importance of lncRNA-based machines in vivo. While
this study defines a role for Firre in a hematopoietic context, it is
important to note that deletion of Firre perturbed gene expression
in a number of tissues, including the brain, where FIRRE has been
implicated in a rare human disease28. Therefore, going forward it
will be important to use genetic models to investigate the
potential role(s) of Firre in a number of different biological and
disease contexts.
Methods
Mouse care and ethics statement. Mice used in this study were maintained in a
pathogen-specific free facility that is under the supervision of Harvard University’s
Institutional Animal Care Committee. We have complied with the ethical reg-
ulations for animal testing and research in accordance with Harvard University’s
Institutional Animal Care and Use Committee.
Mice used in this study were housed at a density of 2–5 mice per cage
containing: Anderson’s Bed (The Andersons, Inc), Enviro-Dri (Shepherd Specialty
Papers), compressed 2” × 2” cotton nestlet (Ancare), a red mouse hut (BioServ),
automatic watering of reverse osmosis deionized water was chlorinated at 2 ppm,
and were fed a regular chow diet (Prolab IsoPro RMH 3000 5P75/76).
Firre mouse strains and genotyping. A previously targeted allele for Firre in JM8
embryonic stem cells (mESC) was generated by sequential targeting where a floxed-
neomycin-floxed cassette was inserted at the 5′ end of the Firre locus between
nucleotides 4790843 and 4790844 (mm9), and a floxed-hygromycin-floxed cassette
was inserted at the 3′ end of the Firre locus between nucleotides 47990293 and
47990294 (mm9)15. mESCs containing both correctly targeted neomycin and
hygromycin cassettes (Firrefloxed) were injected into blastocysts (Harvard Genome
Modification Facility), and subsequent progeny were screened for the Firrefloxed
allele (Jackson Laboratory, 029931). To generate a deletion of the Firre locus in all
tissues, female Firrefloxed mice were mated to male B6.C-Tg(CMV-Cre)1Cgn/J
mice39 (CMV-Cre) (Jackson Laboratory, 006054). We screened the progeny for the
ΔFirre allele by PCR genotyping (described below) for Firre wild-type, knockout
(ΔFirre), neomycin, hygromycin, and cre alleles (Supplementary Fig. 1A, B). A
female containing the ΔFirre and CMV-Cre alleles was subsequently mated to male
C57BL/6J mice in order to remove CMV-Cre and to propagate the ΔFirre allele.
Progeny were PCR genotyped for Firre wild-type, ΔFirre, and cre alleles. Progeny
containing only the ΔFirre allele were backcrossed to C57BL/6J mice for three
generations (N3) (Jackson Laboratory, 030038). Mice were inbred by intercrosses
by heterozygous and homozygous breeding strategies.
To generate an inducible Firre-overexpressing allele (tg(Firre)) in mice, we
cloned a mouse Firre cDNA15 into a Tet-On vector (pTRE2), where the β-globin
intron sequence was removed. The construct was verified by Sanger DNA
sequencing. Next, we used EcoRI and NheI restriction enzymes to digest the
cassette containing the tet-responsive element, CMV minimal promoter, Firre
cDNA, and β-globin poly(A) terminator. The digested DNA fragment was purified
according to Harvard Genome Modification Facility protocol, and the purified
DNA cassette was injected into the pronucleus of C57BL/6J zygotes (Harvard
Genome Modification Facility). Progeny were screened for the tg(Firre) cassette by
PCR genotyping for the tg(Firre) allele, and male founder mice were identified and
individually mated to female C57BL/6J mice (Jackson Laboratory, 000664). To
overexpress tg(Firre) N2 and N3 generation, females were mated to male B6N.FVB
(Cg)-Tg(CAG-rtTA3)4288Slowe/J (rtTA) mice (Jackson Laboratory, 016532) and
at the plug date females, and the subsequent progeny were either placed on a
normal chow diet or 625 mg/kg doxycycline-containing chow (Envigo, TD.01306)
until the experimental end points. A colony of male rtTA mice were maintained by
breeding to C57BL6/J females for up to four generations.
Genotyping for mice was performed on tissue biopsies that were mixed with
200 µL of digest buffer (50 mM KCl, 10 mM Tris–HCl pH 8.3, 2.5 mM MgCl2,
0.1 mg/mL gelatin, 0.45% NP40, and 0.45% Tween-20 in ddH2O with 10 µg/mL
proteinase K) in a 1.5 -mL eppendorf tube, and were incubated for 6–18 h at 54 °C.
Next, samples were placed on a heating block at 100 °C for 5 minutes (min) in
order to heat inactivate proteinase K. Genotyping was performed by PCR using 2x
PCR Super Master Mix (Biotool, B46019) and Quick-Load Taq 2X Master Mix
(NEB, M0271L) with the cycling conditions 94 °C for 3 min, followed by 35 cycles
of 94 °C for 20 s, 55 °C for 30 s, 72 °C for 45 s. Primers used for genotyping: Firre
wild-type allele, F: GGAGGAGTGCTGCTTACTGG, R: TCTGTGAGCCACCTG
AAATG; ΔFirre allele, F: TCACAATGGGCTGGGTATTCTC, R: CCTGGGTCC
TCTATAAAAGCAACAG; neomycin, F: GACCACCAAGCGAAACATC, R: CT
CGTCAAGAAGGCGATAGAA; hygromycin, F: CGGAAGTGCTTGACATTG
GG, R: CGTCCATCACAGTTTGCCAGTG; Cre, F: TAATCCATATTGGCAGA
ACG, R: ATCAATCGATGAGTTGCTTC; Sry, F: TTGTCTAGAGAGCATGGAG
GGCCATGTCAA, R: CCACTCCTCTGTGACACTTTAGCCCTCCGA; tg(Firre)
allele, F: TACCACTCCCTATCAGTGA, R: CGGCTTCATCTTCAGTCCTC; and
the rtTA allele, F: AGTCACTTGTCACACAACG, R: CTCTTATGGAGATCCC
TCGAC. Additional genotyping was performed by Transnetyx using real-
time PCR.
Cytokine analysis and in vivo endotoxin challenge. To investigate the cytokine
response in vivo, we used two different preparations of LPS from Escherichia coli
(E. coli) O111:B4. (Sigma, L2630) and Ultrapure LPS, E. coli O111:B4 (InvivoGen,
tlrl-3pelps) and dissolved in 0.9% saline solution (Teknova, S5825). We adminis-
tered either 0.9% saline or 5 mg/kg broad-acting LPS (Sigma, L2630) by i.p.
injection using 30-G insulin syringes (BD, 328411) to two female mice cohorts
8–10 weeks old (WT, ΔFirre, FirreOE no dox, and dox fed FirreOE). We also
administered a different preparation of LPS at 5 mg/kg that is TLR4-specific
(InvivoGen, tlrl-3pelps) by i.p. injection in mice 5–10 weeks old (WT, FirreOE no
dox, and dox fed FirreOE). At 5 h post i.p. injection, mice were euthanized, and
peripheral blood was collected by cardiac puncture and allowed to clot for 30 min
at room temperature with gentle rotation. After clotting, samples were centrifuged
at 1000×g for 10 min at 4 °C, and serum was collected. Cytokine analysis was
performed on serum diluted twofold in PBS pH 7.4 (Eve Technologies, Chemokine
Array 31-Plex). Measurements within the linear range of the assay are reported.
Endotoxin survival experiments were performed over two independent
experiments using mice 9–16 weeks old: WT (mean age= 12.9 weeks), ΔFirre
(mean age= 16 weeks), FirreOE no dox (mean age= 13.6 weeks), and dox fed
FirreOE (mean age= 13.7 weeks). Saline control group consisting of WT, ΔFirre,
and FirreOE mice. In all, 0.9% saline or 5 mg/kg LPS (InvivoGen, tlrl-3pelps) was
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prepared as described above and administered by i.p. injection, and mice were
monitored for moribund survival over 6 days. Mice were housed at a density of 3–5
mice per cage containing: Anderson’s Bed (The Andersons, Inc), Enviro-Dri
(Shepherd Specialty Papers), compressed 2” × 2” cotton nestlet (Ancare), and a red
mouse hut (BioServ). The following supportive care was provided during the
duration of the experiments: hydrogel, a small cup containing powdered diet mixed
with water, and a heating pad (5” × 8.6” × 6”) was placed externally on the bottom
of the cage (Kobayashi).
Whole-mount in situ hybridization. We generated a digoxigenin-labeled anti-
sense riboprobe by in vitro transcription (Roche, 11277073910) against Firre from
a 428 bp sequence (Supplementary Fig. 1C) that corresponds to the 5′ end of the
Firre transcript. In situ hybridization was performed on a minimum of three
embryos per stage and/or genotype. For whole-mount staining, we fixed embryos
in 4% paraformaldehyde for 18 h at 4 °C, followed by three washes in 1× PBS for
10 min at room temperature. We then dehydrated the embryos for 5 min at room
temperature in a series of graded methanol solutions (25%, 50%, 75%, methanol
containing 0.85% NaCl, and 100% methanol). Embryos were stored in 100%
methanol at -20 °C. Next, we rehydrated embryos through a graded series of 75%,
50%, 25% methanol/0.85% NaCl solutions for 5 min at room temperature.
Embryos were next washed twice in 1x PBS with 0.1% Tween-20 (PBST) and
treated with 10 mg/mL proteinase K in 1x PBST for 10 min (E8.0, E9.5) or 30 min
(E10.5, E11.5, and E12.5). Samples were fixed again in 4% paraformaldehyde/0.2%
glutaraldehyde in PBST for 20 min at room temperature, and washed twice in 1x
PBST. We then incubated samples in pre-hybridization solution (50% formamide,
5× saline–sodium citrate (SSC) pH 4.5, 50 μg/ml yeast RNA, 1% SDS, 50 μg/ml
heparin, and nuclease-free ddH2O) for 1 h at 68 °C, and then incubated samples in
500 ng/mL of Firre antisense riboprobe at 68 °C for 16 h. Post hybridization,
samples were washed in stringency buffers and incubated in 100 μg/mL RNaseA at
37 °C for 1 h. Next, samples were washed in 1× maleic acid buffer with 0.1%
Tween-20 (MBST) and incubated in Roche Blocking Reagent (Roche, 1096176)
with 10% heat-inactivated sheep serum (Sigma, S2263) for 4 h at room tempera-
ture. We used an anti-digoxigenin antibody (Roche, 11093274910) at 1:5000 and
incubated the samples for 18 h at 4 °C. Samples were washed eight times with
MBST for 15 min, five times in MBST for 1 h, and then once in MBST for 16 h at
4 °C. Samples were washed 3x for 5 min at room temperature with NTMT solution
(100 mM NaCl, 100 mM Tris–HCl (pH 9.5), 50 mM MgCl2, 0.1% Tween-20, 2 mM
levamisole). The in situ hybridization signal was developed by adding BM Purple
(Roche, 11442074001). After the colorimetric development, samples were fixed in
4% paraformaldehyde and cleared through a graded series of glycerol/1X PBS and
stored in 80% glycerol. Embryos were imaged with a Leica M216FA stereo-
microscope (Leica Microsystems) equipped with a DFC300 FX digital imaging
camera in Leica Application Suite v2.3.4 R2.
RNA-seq in embryonic tissues preparation and analysis. For WT and ΔFirre
RNA-seq in embryonic tissues, we dissected tissues (forebrain, midbrain, heart,
lung, liver, forelimb, hindlimb, and pre-somitic mesoderm) from E11.5 embryos
(44–48 somites) that were collected from matings between either male WT and
female Firre+/− or male ΔFirre and female Firre+/− mice. Tissues were immedi-
ately homogenized in Trizol (Invitrogen), and the total RNA was isolated using
RNeasy mini columns (Qiagen) on a QIAcube (Qiagen). Samples were genotyped
for the WT, ΔFirre, and sex alleles. For each tissue, we generated the following
libraries: WT male (n= 3), WT female (n= 3), ΔFirre male (n= 3), and ΔFirre
female (n= 3). Poly(A)+ RNA-seq libraries were constructed using TruSeq RNA
Sample Preparation Kit v2 (Illumina). The libraries were prepared using 500 ng of
the total RNA as input, with the exception of the lung (200 ng) and the pre-somitic
mesoderm (80 ng), and with a 10-cycle PCR enrichment to minimize PCR artifacts.
The indexed libraries were pooled in groups of six, with each pool containing a mix
of WT and ΔFirre samples. Pooled libraries were sequenced on an Illumina HiSeq
2500 in rapid-run mode with paired-end reads.
Reads were mapped to the mm10 mouse reference genome using TopHat v2.1.1
with the flags: "--no-coverage-search --GTF gencode.vM9.annotation.gtf", where
this GTF is the Gencode vM9 reference gene annotation available at gencodegenes.
org. Cufflinks v2.2.1 was used to quantify gene expression and assess the statistical
significance of differences between conditions. Cuffdiff was used to independently
compare the WT and ΔFirre samples and from each tissue and sex, and genes with
FDR ≤0.05 were deemed significant (Supplementary Data 1–8). Gene Ontology
analysis was performed using genes found significantly dysregulated in four or
more embryonic tissues using FuncAssociate 3.058.
RNA-seq in CLPs preparation and analysis. We isolated CLPs (Lin–Sca1locK-
itloIL7Rα+)by fluorescence-activated cell sorting (FACS) from mice 27–32 weeks
old: WT (n= 4, mean age= 31 weeks), ΔFirre (n= 4, mean age= 30.4 weeks), and
Firrerescue +dox (n= 4, mean age= 29.3 weeks. CLPs were directly sorted into
TRIzol. RNA was isolated using RNeasy micro columns (Qiagen, 74004) on a
QIAcube (Qiagen), and we quantified the concentration, and determined the RNA
integrity using a BioAnalyzer (Agilent). Poly(A)+ RNA-seq libraries were con-
structed using CATS RNA-seq kit v2 (Diagenode, C05010041). Pooled libraries
were sequenced on an Illumina HiSeq 2500 in rapid-run mode with paired-
end reads.
The adapter-trimmed reads were mapped to the mm10 mouse reference
genome using TopHat v2.1.1 with the flags: “--no-coverage-search --GTF gencode.
vM9.annotation.gtf ” (Gencode vM9 reference gene annotation). FeatureCounts
v1.6.2 and DESeq2 v1.14.1 were used to quantify gene expression and assess the
statistical significance of differences between conditions59,60 and the P-value of
comparisons were empirically calculated by using fdrtools v1.2.15 (ref.61). Genes
with an FDR ≤0.1 were deemed significant in a comparison between wild-type and
ΔFirre (Supplementary Data 9) and genes with an FDR ≤0.1 in the ΔFirre and
Firrerescue comparison were deemed significant (Supplementary Data 10). Gene
Ontology analysis was performed on significantly differentially regulated genes
(FDR ≤0.1) in the WT and ΔFirre CLP comparison using PANTHER62.
qRT-PCR. Embryonic tissues or cells were homogenized in Trizol (Invitrogen), and
total RNA was isolated using RNeasy mini columns (Qiagen) on a QIAcube
(Qiagen). In total, 300 ng of the isolated RNA was used as input to synthesize
cDNA (SuperScript IV VILO Master Mix, Invitrogen, 11756050). Primers used
qRT-PCR experiments: F_b-act: GCTGTATTCCCCTCCATCGTG, R_b-act:
CACGGTTGGCCTTAGGGTTCAG; F_Firre: AAATCCGAGGACAGTCGAGC,
R_Firre: CCGTGGCTGGTGACTTTTTG. Experiments were performed on a Viia7
(Applied Biosciences). qRT-PCR data were analyzed by the ΔΔCt method63.
Distribution of Firre expression across wild-type tissues. For each of the eight
WT embryonic tissues, FPKM estimates of all protein-coding or noncoding genes
(biotypes selected: protein coding, lincRNA, and processed transcript) were
aggregated and filtered for expression > 1 FPKM. Density and expression plots were
generated using ggplot2_2.2.1 (geom_density()) in R version 3.3.3.
Flow-cytometry analysis. Zombie Aqua Fixable Viability Kit (Biolegend, 423101)
was used as a live-dead stain, and used according to the manufacturer’s protocol. For
cell analysis of the peripheral blood, thymus, and bone marrow, age and sex-matched
mice were used. Peripheral blood was collected by cardiac puncture or by tail vein
collection into 10% by volume 4% citrate solution. The following antibodies were
added (1:100) to each sample and incubated for 30min at room temperature Alexa
Fluor 700 anti-mouse CD8a clone 53-6.7 (Biolegend, 100730), PE/Dazzle-594 anti-
mouse CD4 clone GK1.5 (Biolegend, 100456), APC anti-mouse CD19 clone 6D5
(Biolegend, 115512), Alexa Fluor 488 anti-mouse NK-1.1 clone PK136 (Biolegend,
108718), PE anti-mouse CD3 clone 17A2 (Biolegend, 100205), and TruStain FcX
(anti-mouse CD16/32) clone 93 (1:50) (Biolegend, 101319). For competitive chimera
experiments, Pacific Blue anti-mouse CD45.2 clone 104 (Biolegend, 109820) and
PerCP anti-mouse CD45.1 clone A20 (Biolegend, 110726) were also used. Red blood
cells were then lysed for 15min at room temperature using BD FACS Lysing Solution
(BD, 349202). Cells were washed twice in 1x PBS with 1% BSA and then resuspended
in 1% paraformaldehyde or 1x PBS with 0.2% BSA.
Thymi were collected and homogenized in ice cold PBS over a 40-micron filter.
The cells were incubated with the following antibodies (1:100) for 30 min at room
temperature: Alexa Fluor 488 anti-mouse CD25 clone PC61 (Biolegend, 102017),
PE/Cy7 anti-mouse/human CD44 clone IM7 (Biolegend, 103030), PE anti-mouse
TCR β chain clone H57-597 (Biolegend, 109208), APC anti-mouse/human CD45R/
B220 clone RA3-6B2 (Biolegend, 103212), eFluor 450 anti-mouse CD69 clone
H1.2F3 (Invitrogen/eBioscience, 48069182), Alexa Fluor 700 anti-mouse CD8a
clone 53-6.7 (Biolegend, 100730), and PE/Dazzle-594 anti-mouse CD4 clone GK1.5
(Biolegend, 100456). Cells were washed twice in 1x PBS with 1% BSA and then
resuspended in 1% paraformaldehyde.
Bone marrow was collected from both femurs and tibias (four bones total per
mouse) by removing the end caps and flushing with DMEM (Gibco, 11995-073)
containing 5% fetal bovine serum (FBS) (Gibco, 26140079) and 10 mM EDTA.
Cells were then pelleted, resuspended, and passed through a 70-micron filter. The
resulting single-cell suspension was then incubated with the following antibodies
(1:100) for 60 min on ice: Alexa Fluor 700 anti-mouse CD16/CD32 clone 93
(Invitrogen/eBioscience, 56-0161-82), PE/Cy7 anti-mouse CD127 (IL-7Rα) clone
A7R34 (Biolegend, 135014), Alexa Fluor 488 anti-mouse CD117 (c-Kit) clone 2B8
(Biolegend, 105816), PE/Dazzle-594 anti-mouse Ly-6A/E (Sca1) clone D7
(Biolegend, 108138), APC anti-mouse CD34 clone HM34 (Biolegend, 128612), PE
anti-mouse CD135 clone A2F10 (Biolegend, 135306), and Pacific Blue anti-mouse
Lineage Cocktail (20 μL per 1×106 cells) clones 17A2/RB6-8C5/RA3-6B2/Ter-119/
M1/70 (Biolegend, 133310). Red blood cells were lysed for 15 min at room
temperature using BD FACS Lysing Solution (BD, 349202) or BD Pharm Lyse (BD,
555899). Cells were washed twice in 1x PBS with 1% BSA and then resuspended in
1% paraformaldehyde or 1x PBS with 0.2% BSA.
Flow cytometry was performed on a LSR-II (BD). To enumerate cell
populations, 50 μL of CountBright Absolute Counting Beads (Invitrogen, C36950)
was added to relevant bone marrow and thymus samples. Gating of cell
populations was performed using FlowJo 10.4.1 software (Treestar) using the
following criteria (applied to live singlets) (Supplementary Fig. 10): CD4 T cells
(CD3+CD4+CD8-CD19-); CD8 T cells (CD3+CD8+CD4-CD19-); NK cells
(NK1.1+CD19-CD3-); B cells (CD19+CD3-); double negative (DN) (B220-CD4-
CD8-CD25varCD44var); double positive (DP) (CD4+CD8+B220-); single positive
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(SP) (CD8, CD8+CD4-B220-); single positive (SP) (CD4, CD4+CD8-B220-);
hematopoietic stem cells (HSC) (LSK [Lin-], Sca1+, c-Kit+)-CD34+-CD135-);
multipotent progenitors (MPP) (LSK[CD34+CD135+]); common lymphoid
progenitors (CLP) (Lin-Sca1loc-KitloIL7Rα+); and common myeloid progenitors
(CMP) (LK[CD34+CD16/32-]). Negative gates were set using fluorescence-minus-
one controls (FMO).
Competitive HSC transplant assay. Bone marrow from age- and sex-matched
mice was collected and pooled with like genotypes (as described in flow-cytometry
analysis section) from mice that were 8–9 weeks in age: PepBoy/CD45.1 (n= 3
females per experiment; mean age= 9 weeks) (Jackson Laboratory, 002014), Firre
WT/CD45.2 (n= 3 females per experiment mean age= 8.9 weeks), and ΔFirre/
CD45.2 (n= 3 females per experiment; mean age= 8.6 weeks). Bone marrow was
lineage-depleted according to the manufacturer's protocol (MiltinyiBiotec, 130-
042-401), and cell marker surface staining was performed (as described for bone
marrow in the Flow-cytometry analysis section). Red blood cells were then lysed
for 15 min at room temperature using BD Pharm Lyse (BD, 555899). Cells were
washed twice in 1x Hank’s balanced salt solution (HBSS) (Gibco, 14025092) with
5% FBS and 2mM EDTA. We then double-sorted lineage-depleted cells for an
HSC-enriched population (Live, Lin-Sca1+c-Kit+CD34+-CD135-) into HBSS with
2% FBS using FACS (BD Aria). Recipient mice, PepBoy/CD45.1 (n= 10 males per
experiment; mean age= 8.6 weeks), were lethally irradiated using a split 9.5γ split
dose (3 h apart). Firre WT and ΔFirre HSCs were separately mixed at a 1:1 ratio
with PepBoy/CD45.1 HSCs. In total, 100 μl containing 4000 mixed cells were
transplanted by retro-orbital injection using 30-gauge insulin syringes (BD,
328411) into lethally irradiated recipients. Forty-eight hours post transplant,
100,000 helper marrow cells from male PepBoy/CD45.1 were transplanted by
retro-orbital injection into each experimental PepBoy/CD45.1 male recipient
mouse. After transplantation, mice were maintained on antibiotic-containing water
(0.4% sulfamethoxazole/0.008% trimethoprim) for 4 weeks, and then switched to
automatic watering of reverse osmosis deionized water chlorinated at 2 ppm.
MEF preparations and culture. We generated Firre WT, Firre knockout, and Fir-
rerescue MEFs at E13.5 from intercrosses between male Firre-/y with female Firre+/−
and male Firrerescue with female Firre−/−. Individual embryos were dissected into 1x
phosphate-buffered saline (PBS) and were eviscerated, and the head, forelimbs, and
hindlimbs were removed. Embryo carcasses were placed into individual 6 cm2 tissue
culture plates containing 1mL of pre-warmed 37 °C TrypLE (Thermo Fisher,
12604013) and were incubated at 37 °C for 20min. Embryos were dissociated by
gently pipetting using a P1000 tip and MEF media was added. Cells were cultured for
5–7 days, and cryostocks of individual lines were generated. Subsequent experiments
were performed from thaws from the cryostocks up to passage 3. MEFs were geno-
typed for Firre WT, knockout, rtTA, tg(Firre), and sry alleles. MEF culture media: 1x
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen 11965-118), 10% FBS
(Gibco, 10082139), L-glutamine (Thermo Fisher, 25030081), and penicillin/strepto-
mycin (Thermo Fisher, 15140122).
Firre FISH probe design and RNA FISH. Firre oligo probes were designed using
Primer3 (http://frodo.wi.mit.edu/primer3/), and synthesized by Integrated DNA
Technologies. After Amine-ddUTP (Kerafast) was added to 2 pmol of pooled oligos
by terminal transferase (New England Biolabs), oligos were labeled with Alexa647
NHS-ester (Life Technologies) in 0.1 M sodium borate. Firre RNA FISH was
performed on Firre WT, ΔFirre, and Firrerescue MEFs which were plated at a
density of 50,000 cells per well onto round glass coverslips in a 24-well plate.
Firrerescue MEFs were cultured with either 2 µg/mL dox (Sigma, D9891) or vehicle
(ddH2O) for 24 h. Replicate wells were processed for either RNA FISH or to isolate
RNA for Firre induction analysis by qRT-PCR. For RNA FISH, cells grown on glass
coverslips were rinsed with 1x PBS and then fixed in 4% paraformaldehyde for
10 min at room temperature. Cells were permeabilized with 0.5% Triton X-100 in
1x PBS for 3 min at room temperature and then washed two times with 1x PBS for
5 min at room temperature. Cells were then dehydrated in a series of increasing
ethanol concentrations. Six labeled oligo probes were added to hybridization buffer
containing 25% formamide, 2X SSC, 10% dextran sulfate, and 1 mg/mL yeast
tRNA. RNA FISH was performed in a humidified chamber at 42 °C for 4 h. Cells
were washed three times in 2× SSC, and then were mounted for wide-field fluor-
escent imaging or dehydrated for STORM imaging. Nuclei were counter-stained
with Hoechst 33342 (Life Technologies). The following pooled oligos against Firre
were used: (1) AGCAGCAAATCCCAGGGGCC, (2) TTCCTCATTCCCCTTCTC
CTGG, (3) CCCATCTGGGTCCAGCAGCA, (4) ATCAGCTGTGAGTGCCTTGC,
(5) TCCAGTGCTTGCTCCTGATG, (6) GCCATGGTCAAGTCCTGCAT.
Firre DNA/RNA and Xist RNA co-FISH. Primary MEF cells were trypsinzed and
cytospun to glass slides. After brief air drying, cells were incubated in PBS for
1 min, CSK/0.5% Triton X-100 for 2 min on ice, and CSK for 2 min on ice. Cells
were fixed in 4% formaldehyde in PBS for 10 min at RT and washed twice in PBS.
After dehydrated through series of EtOH washes, cells were subject to hybridiza-
tion at 37 °C O/N with denatured digoxigenin-labeled Xist probe (50% formamide,
2× SSC, 10% dextran sulfate, 0.1 mg/mL CoT1 DNA). Cells were washed in 50%
formamide, 2× SSC at 37 °C, and in 2× SSC at RT, three times each. RNA FISH
signal was detected by incubating FITC-labeled anti-digoxygenin antibody (Roche)
in 4× SSC, 0.1% Tween-20 at 37 °C for 1 h and followed by washing in 4× SSC,
0.1% Tween-20 at 37 °C three times. Cells were fixed again in 4% formaldehyde in
PBS for 10 min and washed twice in PBS. Cellular RNAs were removed by RNase A
(Life Technologies) in PBS at 37 °C. After dehydrated through series of EtOH, cells
were sealed in hybridization buffer (50% formamide, 2× SSC, 10% dextran sulfate,
0.1 mg/mL CoT-1 DNA) containing Cy3-labeled Firre probe (Fosmid WI-755K22).
Chromosomal DNA and probes were denatured at 80 °C for 15 min and allowed to
renature by cooling down to 37 °C O/N. Cells were washed in 50% formamide, 2×
SSC at 37 °C and in 2× SSC at RT, three times each. Nuclei were counter-stained
with Hoechst 33342 (Life Technologies). Imaging was performed on a Nikon 90i
microscope equipped with a 60X/1.4 N.A. VC objective lens, Orca ER camera
(Hamamatsu), and Volocity software (Perkin Elmer). All probes were prepared by
nick translation using DNA polymerase I (New England Biolab), DNase I (Pro-
mega), and Digoxigenin-dUTP (Roche), or Cy3-dUTP (Enzo Life Sciences).
Skeletal preparations. WT and ΔFirre E18.5 embryos were dissected and evis-
cerated. Samples were fixed in 100% ethanol for 24 h at room temperature.
Embryos were then placed in 100% acetone for 24 h at room temperature and then
incubated in staining solution (0.3% alcian blue 8GS (Sigma) and 0.1% Alizarin
Red S (Sigma) in 70% ethanol containing 5% acetic acid) for 3 days at 37 °C.
Samples were rinsed with distilled water and then placed in 1% potassium
hydroxide at room temperature for 24 h. Samples were cleared in a series of
incubations with 1% potassium hydroxide in 20%, 50%, and 80% glycerol. Skeletal
preparations were placed in 80% glycerol/1x PBS and imaged using a Nikon D7000
camera with a Nikon 28-105 macro lens. Images were captured in the Nikon
Electronic Format (NEF), and were processed in the Adobe Camera Raw plugin
where exposure and temperature adjustments were applied to all like images.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNA-sequencing data is available at Gene Expression Omnibus under the accession
numbers GSE125683 and GSE83631. The data that support the findings of the study are
available from the corresponding author upon request.
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